Nursing high dose intravenous immunoglobulin therapy of Kawasaki
disease
Ni LF, Liu XL, Wang Li,
Wu M, Liao JX, Li CR
Shenzhen Children¡¯s
Hospital, Shenzhen 518026, China
Objective: To explore the nursing of
high dose intravenous immunoglobulin (hdIVIg) therapy of Kawasaki disease,
its efficacy and safety.
Methods: 71 patients
with Kawasaki disease were retrospectively reviewed about the dosage,
administration, intravenous drip duration, efficacy, and nursing.
Results: From
December 1999 to February 2001 there were 60 of 71 patients with Kawasaki
disease accepted hdIVIg as major treatment. 10() treated with 1g/kg body
weight, 49(81.67%) with 2g/kg intravenous immunoglobulin. The concentration
of immunoglobulin was 5%. The drip speed started slowly, if there was no
any adverse reaction after 15 minutes, the speed might increased to no more
than 2ml/minutes. 15(25%) completed the regimen within one day, and
35(58.33%) completed the regimen within two days. Fever disappeared within
24 hours in 30 of 60 patients, and another 20 within the second 24 hours.
By one month after the disease onset, only one patient had coronary artery
aneurysm. Only one patient complained having headache, looked pale, but the
life signs was normal, and ultimately completed the treatment.
Conclusion: High dose of
intravenous immunoglobulin therapy of Kawasaki disease is efficacious and
safe. We cumulated many experiences about the nursing of hdIVIg therapy.